Literature DB >> 1904902

Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis.

M Barral-Netto1, A Barral, S B Santos, E M Carvalho, R Badaro, H Rocha, S G Reed, W D Johnson.   

Abstract

In visceral leishmaniasis (VL), patient's lymphocytes are not activated by leishmania Ag stimulation, and their sera exhibit a potent nonspecific suppressive effect on the responses of normal lymphocytes. Sera were obtained from 33 VL patients, eight patients with subclinical VL, and from 27 normal volunteers. Only sera from VL patients markedly reduced Con A-induced lymphocyte proliferative responses, as well as IL-2 or IFN-gamma production by normal lymphocytes. Addition of exogenous human rIL-2 to cultures containing VL patient sera partially reversed the normal lymphocyte proliferative capacity and restored IFN-gamma production. This phenomenon was consistent with the presence of greatly elevated levels of soluble IL-2R (sIL-2R) in VL patients' sera (4299 +/- 2351 U/ml), well above those of normal sera (180 +/- 94 U/ml), or of sera from patients with subclinical leishmania infection without immunosuppression (1002 +/- 281 U/ml). Furthermore, the removal of sIL-2R reduced VL serum suppressive activity as evaluated by effects on IL-2 and on IFN-gamma production. These data suggest the participation of high levels of sIL-2R in the serum-mediated suppression in VL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904902

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Tuberculin reactivity in tuberculous meningitis.

Authors:  B Mahadevan; S Mahadevan; V Tiroumourougane Serane; R Narasimhan
Journal:  Indian J Pediatr       Date:  2005-03       Impact factor: 1.967

3.  Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.

Authors:  G H Bock; J R Ongkingco; L T Patterson; J Ruley; L R Schroepfer; D L Nelson
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

4.  Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness.

Authors:  N Lahat; R Shtiller; A Y Zlotnick; G Merin
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

5.  Increased capacity for interleukin-2 synthesis parallels disease progression in mice infected with Leishmania major.

Authors:  F P Heinzel; R M Rerko; A M Hujer; R A Maier
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar.

Authors:  Bruno Bucheton; Laurent Abel; Sayda El-Safi; Musa M Kheir; Sylvana Pavek; Arnaud Lemainque; Alain J Dessein
Journal:  Am J Hum Genet       Date:  2003-10-13       Impact factor: 11.025

7.  IL-2 regulation of soluble IL-2 receptor levels following thermal injury.

Authors:  J A Teodorczyk-Injeyan; B G Sparkes; S Lalani; W J Peters; G B Mills
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

Review 8.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Evaluation of serum levels of soluble CD4, CD8 and beta 2-microglobulin in visceral human leishmaniasis.

Authors:  G Vitale; C Mocciaro; R Malta; G Gambino; A Spinelli; C Giordano; G Stassi; F Arcoleo; S Milano; E Cillari
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

10.  The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients.

Authors:  G Vitale; G Reina; S Mansueto; R Malta; G Gambino; C Mocciaro; R D'Agostino; M Dieli; E Cillari
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.